martes, 22 de enero de 2019

How Celgene leaves a legacy of chutzpah in science and drug pricing

How Celgene leaves a legacy of chutzpah in science and drug pricing

Cancer Briefing

Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing

By MATTHEW HERPER


MIKE DERER/AP
Want to know why an industry that views itself as lifesaving and heroic is viewed by much of the public as price gouging and venal? Look here.

No hay comentarios: